eravacycline dihydrochloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 5294 | 1334714-66-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Eravacycline is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 2.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.18 % | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 20, 2018 | EMA | TETRAPHASE PHARMS | |
| Aug. 27, 2018 | FDA | TETRAPHASE PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infectious disease of abdomen | indication | 128070006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.13 | acidic |
| pKa2 | 8.11 | acidic |
| pKa3 | 10.06 | acidic |
| pKa4 | 11.96 | acidic |
| pKa5 | 12.87 | acidic |
| pKa6 | 13.5 | acidic |
| pKa7 | 9.56 | Basic |
| pKa8 | 8.88 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | June 3, 2020 | RX | POWDER | INTRAVENOUS | 8796245 | Aug. 7, 2029 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER |
| EQ 50MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | Aug. 27, 2018 | RX | POWDER | INTRAVENOUS | 8796245 | Aug. 7, 2029 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | June 3, 2020 | RX | POWDER | INTRAVENOUS | Aug. 27, 2023 | NEW CHEMICAL ENTITY |
| EQ 50MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | Aug. 27, 2018 | RX | POWDER | INTRAVENOUS | Aug. 27, 2023 | NEW CHEMICAL ENTITY |
| EQ 100MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | June 3, 2020 | RX | POWDER | INTRAVENOUS | Aug. 27, 2028 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| EQ 50MG BASE/VIAL | XERAVA | TETRAPHASE PHARMS | N211109 | Aug. 27, 2018 | RX | POWDER | INTRAVENOUS | Aug. 27, 2028 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| WK1NMH89VJ | UNII |
| C4723361 | UMLSCUI |
| CHEMBL2219414 | ChEMBL_ID |
| 56951485 | PUBCHEM_CID |
| CHEMBL1951095 | ChEMBL_ID |
| D10369 | KEGG_DRUG |
| 288715 | MMSL |
| 34818 | MMSL |
| 017696 | NDDF |
| DB12329 | DRUGBANK_ID |
| 2055907 | RXNORM |
| C571179 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Xerava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71773-050 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 30 sections |
| Xerava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71773-100 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA | 30 sections |